Patents Assigned to Zhejiang Tianyu Pharmaceutical Co., Ltd.
  • Publication number: 20230242481
    Abstract: Provided is a preparation method for brivaracetam. The method has a synthetic route as shown below.
    Type: Application
    Filed: June 15, 2020
    Publication date: August 3, 2023
    Applicant: Zhejiang Tianyu Pharmaceutical Co., Ltd.
    Inventors: Zhen Wang, Chunlong Ke, Junfeng Liu, Peng Zhang, Qichao Li, Guorong Zhu, Yongjun Tu
  • Publication number: 20220388988
    Abstract: Provided is a preparation method of losartan, which is prepared by reacting a cyano group-containing intermediate represented by formula (I) with an azide reagent in toluene in the presence of a catalyst; wherein, after the reaction is completed, azide ions are removed by means of the following process: adding water to divide the reaction system into three layers, separating the intermediate layer and adding n-butanol to the intermediate layer for dilution, and adding triphenylphosphine to the resulting diluted solution so as to remove residual azide ions from the diluted solution. The preparation method provided by the present invention does not need to use sodium nitrite, thus fundamentally eliminating the formation of genotoxic impurities nitrosamines.
    Type: Application
    Filed: January 17, 2020
    Publication date: December 8, 2022
    Applicant: Zhejiang Tianyu Pharmaceutical Co., Ltd.
    Inventors: Zuwei He, Gang Liu, Dequan Su, Ruiyun Lv, Wei Xiao, Zhen Wang, Guorong Zhu, Yongjun Tu
  • Patent number: 10221145
    Abstract: The present invention discloses a method for preparing an anti-heart-failure medicine LCZ696. The preparing method comprises the following step (formula (I)): in an organic solvent, a Sacubitril dicyclohexylamine salt reacts with valsartan under the effect of a sodium hydroxide aqueous solution, and the anti-heart-failure medicine LCZ696 is obtained. The preparing method of the present invention is simple in process and omits the procedures of ion exchange from a sodium salt to a calcium salt and hydrochloric acid dissociation in an existing production process, residues of calcium ions are avoided, and the production efficiency is effectively improved.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: March 5, 2019
    Assignee: ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
    Inventors: Guorong Zhu, Yongjun Tu, Wenlong Xie, Zhen Wang, Shaojun Xu
  • Patent number: 8664440
    Abstract: A method for preparing Aliskiren and intermediate thereof, which comprises the following steps: reacting 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene with magnesium isopropyl chloride and n-BuLi to obtain the compound of formula XXII; reacting the product of methylsulfonylation of the compound of formula XIX with anhydrous LiBr to obtain the compound of formula XXI; obtaining the intermediate of Aliskiren shown as formula XV by reacting the compound of formula XXII with the compound of formula XXI in an ether as the solvent and in the presence of a catalyst containing iron; then reacting the compound of formula XV with the compound of formula VII to obtain the compound of formula XXIII, following removing R1 from the amino group and obtaining Aliskiren shown as formula I.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: March 4, 2014
    Assignee: Zhejiang Tianyu Pharmaceutical Co., Ltd
    Inventors: Yongjun Tu, Yi Zhang, Rongde Cheng, Lingchao Peng
  • Publication number: 20130225841
    Abstract: A method for preparing Aliskiren and intermediate thereof, which comprises the following steps: reacting 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene with magnesium isopropyl chloride and n-BuLi to obtain the compound of formula XXII; reacting the product of methylsulfonylation of the compound of formula XIX with anhydrous LiBr to obtain the compound of formula XXI; obtaining the intermediate of Aliskiren shown as formula XV by reacting the compound of formula XXII with the compound of formula XXI in an ether as the solvent and in the presence of a catalyst containing iron; then reacting the compound of formula XV with the compound of formula VII to obtain the compound of formula XXIII, following removing R1 from the amino group and obtaining Aliskiren shown as formula I.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 29, 2013
    Applicant: Zhejiang Tianyu Pharmaceutical Co., Ltd.
    Inventors: Yongjun Tu, Yi Zhang, Rongde Cheng, Lingchao Peng